Vanda Pharmaceuticals Inc. - Understand $vnda stock

$VNDA Market Cap: $282.2 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$190.9M

TTM

Gross Margin

93.59%

TTM

Net Earnings

-$16.39M

TTM

Current Assets

$432.4M

Q3 2024

Current Liabilities

$89.09M

Q3 2024

Current Ratio

485.34%

Q3 2024

Total Assets

$645.1M

Q3 2024

Total Liabilities

$103.9M

Q3 2024

Book Value

$541.2M

Q3 2024

Cash

$100.5M

Q3 2024

P/E

-17.22

Nov 29, 2024 EST

Free Cash Flow

-$18.20M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$192.6M	$254.4M	$268.7M	$248.2M	$227.2M	$193.1M	$165.1M	$146.0M	$109.9M	$50.16M	$33.88M	$32.73M	$31.27M	$35.71M	$4.500M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-24.27%	-5.32%	8.27%	9.23%	17.64%	16.98%	13.06%	32.83%	119.16%	48.05%	3.52%	4.66%	-12.43%	693.53%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$192.6M	$254.4M	$268.7M	$248.2M	$227.2M	$193.1M	$165.1M	$146.0M	$109.9M	$50.16M	$33.88M	$32.73M	$31.27M	$35.71M	$4.500M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$14.80M	$24.28M	$25.63M	$23.40M	$24.49M	$20.51M	$17.85M	$24.71M	$23.46M	$1.583M	$0.00	$129.0K	$0.00	$2.891M	$1.900M	$0.00	$0.00
Gross Profit	$177.8M	$230.1M	$243.1M	$224.8M	$202.7M	$172.6M	$147.2M	$121.3M	$86.46M	$48.57M	$33.90M	$32.60M	$31.30M	$32.82M	$2.600M	$0.00	$0.00
Gross Profit Margin	92.32%	90.45%	90.46%	90.58%	89.22%	89.38%	89.19%	83.08%	78.66%	96.84%	100.06%	99.61%	100.1%	91.9%	57.78%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Selling, General & Admin	$112.9M	$136.5M	$124.0M	$140.5M	$129.7M	$105.8M	$123.8M	$99.79M	$84.53M	$84.64M	$25.08M	$14.52M	$11.50M	$10.10M	$23.70M	$26.10M	$29.70M
YoY Change	-17.29%	10.03%	-11.72%	8.3%	22.68%	-14.61%	24.11%	18.05%	-0.13%	237.47%	72.78%	26.23%	13.86%	-57.38%	-9.2%	-12.12%
% of Gross Profit	63.47%	59.32%	51.04%	62.5%	64.0%	61.27%	84.11%	82.26%	97.77%	174.26%	73.99%	44.53%	36.74%	30.78%	911.54%
Research & Development	$76.82M	$85.77M	$75.36M	$55.58M	$48.65M	$43.59M	$38.55M	$29.16M	$29.15M	$19.23M	$28.50M	$45.76M	$29.00M	$12.34M	$13.90M	$23.90M	$47.20M	$52.10M	$16.90M	$7.400M	$2.000M
YoY Change	-10.43%	13.81%	35.6%	14.24%	11.6%	13.09%	32.21%	0.04%	51.56%	-32.53%	-37.72%	57.83%	135.01%	-11.24%	-41.84%	-49.36%	-9.4%	208.28%	128.38%	270.0%
% of Gross Profit	43.2%	37.28%	31.01%	24.72%	24.0%	25.26%	26.18%	24.04%	33.71%	39.59%	84.08%	140.39%	92.64%	37.6%	534.62%
Depreciation & Amortization	$900.0K	$1.200M	$1.400M	$1.400M	$1.400M	$1.400M	$1.200M	$900.0K	$582.0K	$530.0K	$432.0K	$633.0K	$469.0K	$336.0K	$1.400M	$500.0K	$600.0K	$600.0K	$400.0K	$400.0K	$100.0K
YoY Change	-25.0%	-14.29%	0.0%	0.0%	0.0%	16.67%	33.33%	54.64%	9.81%	22.69%	-31.75%	34.97%	39.58%	-76.0%	180.0%	-16.67%	0.0%	50.0%	0.0%	300.0%
% of Gross Profit	0.51%	0.52%	0.58%	0.62%	0.69%	0.81%	0.82%	0.74%	0.67%	1.09%	1.27%	1.94%	1.5%	1.02%	53.85%
Operating Expenses	$189.7M	$222.3M	$199.4M	$196.1M	$178.4M	$149.3M	$162.4M	$128.9M	$113.7M	$103.9M	$53.58M	$60.28M	$29.00M	$12.34M	$38.60M	$52.80M	$80.00M	$52.10M	$16.90M	$7.400M	$2.000M
YoY Change	-14.64%	11.46%	1.69%	9.92%	19.44%	-8.03%	25.94%	13.43%	9.44%	93.85%	-11.11%	107.89%	135.01%	-68.04%	-26.89%	-34.0%	53.55%	208.28%	128.38%	270.0%
Operating Profit	-$13.95M	$6.329M	$42.17M	$27.24M	$22.81M	$21.74M	-$16.90M	-$18.57M	-$40.19M	$20.06M	-$21.20M	-$29.18M	-$10.71M	$8.838M	-$36.00M	-$52.80M	-$80.00M
YoY Change	-320.45%	-84.99%	54.8%	19.42%	4.93%	-228.6%	-8.98%	-53.79%	-300.3%	-194.63%	-27.34%	172.51%	-221.15%	-124.55%	-31.82%	-34.0%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Interest Expense													$500.0K	$400.0K	$100.0K	$1.800M	$5.900M	$2.200M	$400.0K	$100.0K	$0.00
YoY Change													25.0%	300.0%	-94.44%	-69.49%	168.18%	450.0%	300.0%
% of Operating Profit														4.53%
Other Income/Expense, Net	$20.29M	$4.971M	$199.0K	$4.400M	$6.200M	$3.600M	$1.500M	$700.0K	$300.0K	$100.0K	$100.0K	$600.0K			$0.00	$0.00	$100.0K	$0.00	$0.00	$0.00
YoY Change	308.19%	2397.99%	-95.48%	-29.03%	72.22%	140.0%	114.29%	133.33%	200.0%	0.0%	-83.33%					-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Pretax Income	$6.339M	$11.30M	$42.36M	$31.66M	$29.03M	$25.12M	-$15.69M	-$18.10M	-$39.87M	$20.19M	-$20.26M	-$27.66M	-$10.25M	$9.269M	-$35.90M	-$51.10M	-$74.10M	-$49.90M	-$16.50M	-$7.400M	-$1.900M
YoY Change	-43.9%	-73.33%	33.83%	9.05%	15.54%	-260.09%	-13.3%	-54.6%	-297.49%	-199.66%	-26.78%	170.0%	-210.54%	-125.82%	-29.75%	-31.04%	48.5%	202.42%	122.97%	289.47%
Income Tax	$3.830M	$5.025M	$9.212M	$8.318M	-$86.53M	$138.0K	$136.0K	$100.0K	$0.00	$0.00	$0.00	$0.00	-$444.0K	$2.077M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income	60.42%	44.47%	21.74%	26.28%	-298.07%	0.55%				0.0%				22.41%
Net Earnings	$2.509M	$6.275M	$33.15M	$23.34M	$115.6M	$25.21M	-$15.57M	-$18.01M	-$39.87M	$20.19M	-$21.06M	-$28.62M	-$9.802M	$7.192M	-$35.90M	-$51.10M	-$74.10M	-$49.90M	-$16.50M	-$7.400M	-$1.900M
YoY Change	-60.02%	-81.07%	42.06%	-79.8%	358.4%	-261.93%	-13.56%	-54.82%	-297.49%	-195.87%	-26.42%	191.95%	-236.29%	-120.03%	-29.75%	-31.04%	48.5%	202.42%	122.97%	289.47%
Net Earnings / Revenue	1.3%	2.47%	12.34%	9.4%	50.86%	13.05%	-9.43%	-12.33%	-36.27%	40.25%	-62.15%	-87.44%	-31.35%	20.14%	-797.78%
Basic Earnings Per Share	$0.04	$0.11	$0.60	$0.43	$2.17	$0.50	-$0.35	-$0.41	-$0.94	$0.58	-$0.69	-$1.01	-$0.35	$0.26
Diluted Earnings Per Share	$0.04	$0.11	$0.58	$0.42	$2.11	$0.48	-$0.35	-$0.41	-$0.94	$0.55	-$0.69	-$1.01	-$0.35	$0.25	-$1.330M	-$1.914M	-$2.807M	-$3.119M	-$763.9K	-$342.6K	-$87.96K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Cash & Short-Term Investments	$388.3M	$466.9M	$432.8M	$367.7M	$312.1M	$257.4M	$143.4M	$141.3M	$143.2M	$129.8M	$130.4M	$120.4M	$148.9M	$198.0M	$205.3M	$46.50M	$85.20M	$31.90M	$31.20M	$16.30M	$7.200M
YoY Change	-16.83%	7.87%	17.71%	17.81%	21.25%	79.5%	1.49%	-1.33%	10.32%	-0.46%	8.31%	-19.14%	-24.8%	-3.56%	341.51%	-45.42%	167.08%	2.24%	91.41%	126.39%
Cash & Equivalents	$135.8M	$135.0M	$52.07M	$61.00M	$45.10M	$61.00M	$33.60M	$40.40M	$50.80M	$60.90M	$64.80M	$88.80M	$87.90M	$42.60M	$205.3M	$39.10M	$41.90M	$30.90M	$21.00M	$16.30M	$7.200M
Short-Term Investments	$252.4M	$331.8M	$380.7M	$306.7M	$267.1M	$196.4M	$109.8M	$100.9M	$92.30M	$68.90M	$65.60M	$31.60M	$61.00M	$155.5M	$0.00	$7.400M	$43.20M	$900.0K	$10.10M
Other Short-Term Assets	$9.170M	$17.73M	$12.00M	$10.10M	$14.50M	$12.00M	$8.000M	$11.80M	$5.700M	$3.100M	$3.300M	$4.400M	$3.000M	$2.000M	$2.100M	$1.300M	$1.800M	$1.900M	$2.200M	$200.0K	$100.0K
YoY Change	-48.27%	47.77%	18.77%	-30.34%	20.83%	50.0%	-32.2%	107.02%	83.87%	-6.06%	-25.0%	46.67%	50.0%	-4.76%	61.54%	-27.78%	-5.26%	-13.64%	1000.0%	100.0%
Inventory	$1.357M	$1.194M	$1.025M	$1.300M	$1.100M	$1.000M	$800.0K	$800.0K	$1.300M	$5.200M	$0.00			$0.00	$2.400M	$0.00
Prepaid Expenses
Receivables	$34.16M	$33.51M	$32.47M	$30.00M	$26.40M	$28.80M	$17.60M	$20.30M	$16.30M	$3.700M	$2.000M	$1.200M	$1.600M	$500.0K	$3.200M	$0.00				$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00				$0.00	$0.00
Total Short-Term Assets	$432.9M	$519.3M	$478.3M	$409.1M	$354.1M	$299.1M	$169.9M	$174.2M	$166.5M	$141.7M	$135.6M	$126.0M	$153.5M	$200.6M	$213.0M	$47.70M	$87.00M	$33.80M	$33.40M	$16.50M	$7.300M
YoY Change	-16.63%	8.57%	16.92%	15.53%	18.39%	76.04%	-2.47%	4.62%	17.5%	4.5%	7.62%	-17.92%	-23.48%	-5.82%	346.54%	-45.17%	157.4%	1.2%	102.42%	126.03%
Property, Plant & Equipment	$9.140M	$10.97M	$12.39M	$14.60M	$15.00M	$4.400M	$5.300M	$5.000M	$4.600M	$2.400M	$2.200M	$2.300M	$1.000M	$900.0K	$1.300M	$1.800M	$1.300M	$1.900M	$1.100M	$1.300M	$1.100M
YoY Change	-16.7%	-11.4%	-15.17%	-2.67%	240.91%	-16.98%	6.0%	8.7%	91.67%	9.09%	-4.35%	130.0%	11.11%	-30.77%	-27.78%	38.46%	-31.58%	72.73%	-15.38%	18.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments													$19.00M	$0.00		$0.00	$8.100M	$200.0K	$800.0K	$100.0K	$0.00
YoY Change																-100.0%	3950.0%	-75.0%	700.0%
Other Assets	$84.99M	$85.42M	$83.03M	$88.20M	$91.50M	$4.000M	$4.200M	$3.400M	$3.200M	$800.0K	$500.0K	$600.0K	$1.100M	$2.100M	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$0.00
YoY Change	-0.51%	2.88%	-5.87%	-3.61%	2187.5%	-4.76%	23.53%	6.25%	300.0%	60.0%	-16.67%	-45.45%	-47.62%	425.0%	0.0%	0.0%	0.0%	0.0%
Total Long-Term Assets	$215.5M	$115.0M	$115.5M	$124.4M	$129.6M	$33.00M	$35.50M	$36.20M	$46.60M	$30.00M	$7.700M	$9.400M	$29.10M	$12.50M	$12.70M	$2.200M	$9.900M	$2.500M	$2.400M	$1.300M	$1.100M
YoY Change	87.46%	-0.46%	-7.16%	-4.01%	292.73%	-7.04%	-1.93%	-22.32%	55.33%	289.61%	-18.09%	-67.7%	132.8%	-1.57%	477.27%	-77.78%	296.0%	4.17%	84.62%	18.18%
Total Assets	$648.4M	$634.2M	$593.8M	$533.5M	$483.7M	$332.1M	$205.4M	$210.4M	$213.1M	$171.7M	$143.3M	$135.4M	$182.6M	$213.1M	$225.7M	$49.90M	$96.90M	$36.30M	$35.80M	$17.80M	$8.400M
YoY Change
Accounts Payable	$2.409M	$4.979M	$5.873M	$5.800M	$5.900M	$5.200M	$4.400M	$4.600M	$5.300M	$1.400M	$700.0K	$300.0K	$1.000M	$600.0K	$2.400M	$500.0K	$3.000M	$2.800M	$2.300M	$700.0K	$500.0K
YoY Change	-51.62%	-15.22%	1.26%	-1.69%	13.46%	18.18%	-4.35%	-13.21%	278.57%	100.0%	133.33%	-70.0%	66.67%	-75.0%	380.0%	-83.33%	7.14%	21.74%	228.57%	40.0%
Accrued Expenses	$85.29M	$86.46M	$68.55M	$59.80M	$53.60M	$47.60M	$39.00M	$45.80M	$46.00M	$6.300M	$5.200M	$5.200M	$3.400M	$1.300M	$2.300M	$2.900M	$9.800M	$6.300M	$2.500M	$700.0K	$400.0K
YoY Change	-1.35%	26.13%	14.63%	11.57%	12.61%	22.05%	-14.85%	-0.43%	630.16%	21.15%	0.0%	52.94%	161.54%	-43.48%	-20.69%	-70.41%	55.56%	152.0%	257.14%	75.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due																		$0.00	$100.0K	$200.0K	$200.0K
YoY Change																		-100.0%	-50.0%	0.0%
Total Short-Term Liabilities	$87.70M	$91.44M	$74.42M	$65.90M	$59.50M	$53.00M	$70.40M	$50.30M	$51.30M	$7.800M	$32.90M	$32.30M	$31.60M	$31.00M	$31.50M	$3.400M	$12.80M	$9.100M	$5.100M	$1.600M	$1.100M
YoY Change	-4.09%	22.87%	12.93%	10.76%	12.26%	-24.72%	39.96%	-1.95%	557.69%	-76.29%	1.86%	2.22%	1.94%	-1.59%	826.47%	-73.44%	40.66%	78.43%	218.75%	45.45%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$200.0K	$300.0K
YoY Change																			-100.0%	-33.33%
Other Long-Term Liabilities	$15.83M	$15.61M	$14.45M	$14.30M	$13.30M	$3.700M	$3.700M	$28.70M	$28.70M	$3.100M	$66.40M	$93.30M	$117.5M	$144.3M	$171.1M	$500.0K	$400.0K	$400.0K	$0.00	$0.00	$0.00
YoY Change	1.41%	8.09%	1.01%	7.52%	259.46%	0.0%	-87.11%	0.0%	825.81%	-95.33%	-28.83%	-20.6%	-18.57%	-15.66%	34120.0%	25.0%	0.0%
Total Long-Term Liabilities	$15.83M	$15.61M	$14.45M	$14.30M	$13.30M	$3.700M	$3.700M	$28.70M	$28.70M	$3.100M	$66.40M	$93.30M	$117.5M	$144.3M	$171.1M	$500.0K	$400.0K	$400.0K	$0.00	$200.0K	$300.0K
YoY Change	1.41%	8.09%	1.01%	7.52%	259.46%	0.0%	-87.11%	0.0%	825.81%	-95.33%	-28.83%	-20.6%	-18.57%	-15.66%	34120.0%	25.0%	0.0%		-100.0%	-33.33%
Total Liabilities	$103.5M	$107.0M	$88.86M	$80.20M	$72.80M	$56.70M	$74.00M	$79.00M	$80.00M	$10.90M	$99.20M	$125.5M	$149.1M	$175.4M	$202.7M	$3.900M	$13.10M	$9.500M	$5.100M	$1.800M	$1.400M
YoY Change	-3.29%	20.46%	10.8%	10.16%	28.4%	-23.38%	-6.33%	-1.25%	633.94%	-89.01%	-20.96%	-15.83%	-14.99%	-13.47%	5097.44%	-70.23%	37.89%	86.27%	183.33%	28.57%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Basic Shares Outstanding	57.38M shares	56.46M shares	55.55M shares	54.43M shares	53.14M shares	50.86M shares	44.74M shares	43.45M shares	42.25M shares	34.77M shares	30.35M shares	28.23M shares	28.11M shares	27.92M shares
Diluted Shares Outstanding	57.56M shares	56.98M shares	56.92M shares	55.19M shares	54.85M shares	53.05M shares	44.74M shares	43.45M shares	42.25M shares	36.69M shares	30.35M shares	28.23M shares	28.11M shares	28.53M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $282.21 Million

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 203 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The firm also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Industry: Pharmaceutical Preparations Peers: Adicet Bio, Inc. AGENUS INC Century Therapeutics, Inc. Cullinan Therapeutics, Inc. Immunovant, Inc. Janux Therapeutics, Inc. Kezar Life Sciences, Inc. Kinnate Biopharma Inc. PMV Pharmaceuticals, Inc.